TSE:CTX Crescita Therapeutics (CTX) Stock Price, News & Analysis C$0.46 +0.01 (+1.10%) As of 11:13 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesBuy This Stock About Crescita Therapeutics Stock (TSE:CTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Crescita Therapeutics alerts:Sign Up Key Stats Today's RangeC$0.46▼C$0.4650-Day RangeC$0.45▼C$0.5452-Week RangeC$0.45▼C$0.66Volume4,500 shsAverage Volume16,954 shsMarket CapitalizationC$8.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The firm generates its revenue in the form of product sales and out-licensing revenue. Read More Receive CTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crescita Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTX Stock News HeadlinesCrescita Reports Second Quarter 2025 ResultsAugust 6, 2025 | financialpost.comFCrescita Therapeutics Inc. (CTX.TO) - Yahoo FinanceJune 26, 2025 | nz.finance.yahoo.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.August 27 at 2:00 AM | Traders Agency (Ad)Crescita Therapeutics First Quarter 2025 Earnings: CA$0.049 loss per share (vs CA$0.032 loss in 1Q 2024)May 16, 2025 | finance.yahoo.comCrescita Reports First Quarter 2025 ResultsMay 14, 2025 | financialpost.comFCrescita Reports First Quarter 2025 ResultsMay 14, 2025 | financialpost.comFCrescita Therapeutics Inc. (CRRTF)November 24, 2024 | finance.yahoo.comChordia Therapeutics Advances Cancer Drug DevelopmentNovember 20, 2024 | markets.businessinsider.comSee More Headlines CTX Stock Analysis - Frequently Asked Questions How have CTX shares performed this year? Crescita Therapeutics' stock was trading at C$0.58 at the start of the year. Since then, CTX stock has decreased by 20.7% and is now trading at C$0.46. How do I buy shares of Crescita Therapeutics? Shares of CTX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Crescita Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crescita Therapeutics investors own include Baytex Energy (BTE), Argonaut Gold (AR), Birchcliff Energy (BIR), CBTX (CBTX), Crescent Point Energy (CPG), Enbridge (ENB) and IMV (IMV). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CTX CIKN/A Webwww.crescitatherapeutics.com Phone+1-905-6734295FaxN/AEmployees62Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$2.61 million Net Margins-15.73% Pretax MarginN/A Return on Equity-15.60% Return on Assets-8.26% Debt Debt-to-Equity Ratio5.77 Current Ratio2.70 Quick Ratio2.29 Sales & Book Value Annual SalesC$16.62 million Price / Sales0.51 Cash FlowC$0.38 per share Price / Cash Flow1.20 Book ValueC$0.83 per share Price / Book0.55Miscellaneous Outstanding Shares18,406,184Free FloatN/AMarket CapC$8.47 million OptionableNot Optionable Beta1.69 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (TSE:CTX) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescita Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescita Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.